E
Northwest Biotherapeutics, Inc.
NWBO
$0.214
$0.00170.80%
E
Sell
4/18/2024Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to E+ from D- on 4/18/2024 due to a noticeable decline in the solvency index, volatility index and total return index.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to E+ from D- on 4/18/2024 due to a noticeable decline in the solvency index, volatility index and total return index.
D
Sell
4/3/2024Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D- from E+ on 4/3/2024 due to a noticeable increase in the solvency index and volatility index. Debt to equity declined from -0.51 to -0.62.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D- from E+ on 4/3/2024 due to a noticeable increase in the solvency index and volatility index. Debt to equity declined from -0.51 to -0.62.
E
Sell
2/13/2024Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to E+ from D- on 2/13/2024 due to a decline in the volatility index, total return index and growth index.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to E+ from D- on 2/13/2024 due to a decline in the volatility index, total return index and growth index.
D
Sell
1/29/2024Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D- from E+ on 1/29/2024 due to an increase in the volatility index and valuation index.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D- from E+ on 1/29/2024 due to an increase in the volatility index and valuation index.
E
Sell
1/9/2024Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to E+ from D- on 1/9/2024 due to a decline in the volatility index and valuation index.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to E+ from D- on 1/9/2024 due to a decline in the volatility index and valuation index.
D
Sell
10/24/2023Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D- from E+ on 10/24/2023 due to an increase in the volatility index and valuation index.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D- from E+ on 10/24/2023 due to an increase in the volatility index and valuation index.
E
Sell
10/4/2023Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to E+ from D- on 10/4/2023 due to a decline in the volatility index and valuation index.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to E+ from D- on 10/4/2023 due to a decline in the volatility index and valuation index.
D
Sell
9/19/2023Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D- from E+ on 9/19/2023 due to an increase in the volatility index.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D- from E+ on 9/19/2023 due to an increase in the volatility index.
E
Sell
8/29/2023Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to E+ from D- on 8/29/2023 due to a decline in the volatility index and total return index.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to E+ from D- on 8/29/2023 due to a decline in the volatility index and total return index.
D
Sell
8/14/2023Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D- from E+ on 8/14/2023 due to an increase in the volatility index.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D- from E+ on 8/14/2023 due to an increase in the volatility index.
E
Sell
8/2/2023Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to E+ from D- on 8/2/2023 due to a decline in the volatility index and total return index.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to E+ from D- on 8/2/2023 due to a decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
D
Sell
3/3/2023Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D from C- on 3/3/2023 due to a significant decline in the efficiency index, growth index and total return index. Total capital declined 22.1% from -$64.53M to -$78.79M, and EBIT declined 16.39% from -$15.62M to -$18.18M.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D from C- on 3/3/2023 due to a significant decline in the efficiency index, growth index and total return index. Total capital declined 22.1% from -$64.53M to -$78.79M, and EBIT declined 16.39% from -$15.62M to -$18.18M.
C
Hold
3/4/2022Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to C- from D on 3/4/2022 due to a significant increase in the efficiency index, growth index and solvency index. The quick ratio increased from 0.01 to 0.11, debt to equity declined from -0.07 to -0.26, and net income increased 192.89% from $45.52M to $133.32M.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to C- from D on 3/4/2022 due to a significant increase in the efficiency index, growth index and solvency index. The quick ratio increased from 0.01 to 0.11, debt to equity declined from -0.07 to -0.26, and net income increased 192.89% from $45.52M to $133.32M.
D
Sell
11/16/2021Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D from D- on 11/16/2021 due to a noticeable increase in the growth index. EBIT increased 19.01% from -$12.41M to -$10.05M, and earnings per share increased from -$0.0113 to -$0.01.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D from D- on 11/16/2021 due to a noticeable increase in the growth index. EBIT increased 19.01% from -$12.41M to -$10.05M, and earnings per share increased from -$0.0113 to -$0.01.
D
Sell
11/8/2021Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D- from D on 11/8/2021 due to a major decline in the total return index, growth index and solvency index. Earnings per share declined from -$0.0049 to -$0.0113, and the quick ratio declined from 0.02 to 0.01.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D- from D on 11/8/2021 due to a major decline in the total return index, growth index and solvency index. Earnings per share declined from -$0.0049 to -$0.0113, and the quick ratio declined from 0.02 to 0.01.
D
Sell
8/12/2020Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D from C on 8/12/2020 due to a significant decline in the efficiency index, growth index and valuation index. Net income declined 2,225.9% from $2.73M to -$57.95M, earnings per share declined from $0.0045 to -$0.0831, and total capital declined 240.2% from -$17.78M to -$60.47M.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D from C on 8/12/2020 due to a significant decline in the efficiency index, growth index and valuation index. Net income declined 2,225.9% from $2.73M to -$57.95M, earnings per share declined from $0.0045 to -$0.0831, and total capital declined 240.2% from -$17.78M to -$60.47M.
C
Hold
7/23/2020Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to C from C- on 7/23/2020 due to a large increase in the total return index, valuation index and volatility index.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to C from C- on 7/23/2020 due to a large increase in the total return index, valuation index and volatility index.
C
Hold
6/25/2020Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to C- from D on 6/25/2020 due to a significant increase in the efficiency index, total return index and volatility index. Total capital increased 30.39% from -$25.54M to -$17.78M.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to C- from D on 6/25/2020 due to a significant increase in the efficiency index, total return index and volatility index. Total capital increased 30.39% from -$25.54M to -$17.78M.
D
Sell
5/1/2020Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D from D+ on 5/1/2020 due to a significant decline in the efficiency index.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D from D+ on 5/1/2020 due to a significant decline in the efficiency index.
D
Sell
4/20/2020Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D+ from C- on 4/20/2020 due to a substantial decline in the solvency index, total return index and volatility index. The quick ratio declined from 0.04 to 0.01.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D+ from C- on 4/20/2020 due to a substantial decline in the solvency index, total return index and volatility index. The quick ratio declined from 0.04 to 0.01.
C
Hold
6/19/2019Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to C- from C on 6/19/2019 due to a decline in the total return index and volatility index.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to C- from C on 6/19/2019 due to a decline in the total return index and volatility index.
C
Hold
5/15/2019Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to C from D on 5/15/2019 due to a significant increase in the efficiency index, total return index and growth index. Total revenue increased 175.17% from -$451 to $339, and operating cash flow increased 31.22% from -$14.18M to -$9.75M.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to C from D on 5/15/2019 due to a significant increase in the efficiency index, total return index and growth index. Total revenue increased 175.17% from -$451 to $339, and operating cash flow increased 31.22% from -$14.18M to -$9.75M.
D
Sell
4/3/2019Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D from D+ on 4/3/2019 due to a major decline in the growth index, total return index and valuation index. Operating cash flow declined 249.81% from -$4.05M to -$14.18M, total revenue declined 199.56% from $453 to -$451, and earnings per share declined from $0.0182 to -$0.0109.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D from D+ on 4/3/2019 due to a major decline in the growth index, total return index and valuation index. Operating cash flow declined 249.81% from -$4.05M to -$14.18M, total revenue declined 199.56% from $453 to -$451, and earnings per share declined from $0.0182 to -$0.0109.
D
Sell
1/24/2019Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D+ from D on 1/24/2019 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0582 to $0.0182, operating cash flow increased 64.96% from -$11.57M to -$4.05M, and total revenue increased 62.95% from $278 to $453.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D+ from D on 1/24/2019 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0582 to $0.0182, operating cash flow increased 64.96% from -$11.57M to -$4.05M, and total revenue increased 62.95% from $278 to $453.
D
Sell
5/18/2018Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D from D+ on 5/18/2018 due to a significant decline in the efficiency index and volatility index. Total capital declined 97.28% from -$15.86M to -$31.3M.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D from D+ on 5/18/2018 due to a significant decline in the efficiency index and volatility index. Total capital declined 97.28% from -$15.86M to -$31.3M.
D
Sell
4/18/2018Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D+ from D on 4/18/2018 due to a significant increase in the efficiency index, total return index and growth index.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D+ from D on 4/18/2018 due to a significant increase in the efficiency index, total return index and growth index.
D
Sell
1/9/2018Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D from D- on 1/9/2018 due to an increase in the total return index, volatility index and growth index. Total revenue increased 68.18% from $88 to $148.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D from D- on 1/9/2018 due to an increase in the total return index, volatility index and growth index. Total revenue increased 68.18% from $88 to $148.
D
Sell
8/22/2017Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D- from D on 8/22/2017 due to a decline in the growth index and solvency index. The quick ratio declined from 0.02 to 0.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D- from D on 8/22/2017 due to a decline in the growth index and solvency index. The quick ratio declined from 0.02 to 0.
D
Sell
5/17/2017Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D from D- on 5/17/2017 due to a large increase in the efficiency index, growth index and valuation index. Earnings per share increased from -$0.2426 to -$0.08, net income increased 58.9% from -$30.71M to -$12.62M, and EBIT increased 43.98% from -$21.25M to -$11.9M.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to D from D- on 5/17/2017 due to a large increase in the efficiency index, growth index and valuation index. Earnings per share increased from -$0.2426 to -$0.08, net income increased 58.9% from -$30.71M to -$12.62M, and EBIT increased 43.98% from -$21.25M to -$11.9M.
D
Sell
8/10/2016Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D- from D on 8/10/2016 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0625 to -$0.1619, and total revenue declined 33.47% from $236 to $157.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D- from D on 8/10/2016 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0625 to -$0.1619, and total revenue declined 33.47% from $236 to $157.
D
Sell
3/17/2016Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D from D+ on 3/17/2016 due to a significant decline in the efficiency index, total return index and volatility index. Net income declined 206.47% from $22.62M to -$24.08M.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D from D+ on 3/17/2016 due to a significant decline in the efficiency index, total return index and volatility index. Net income declined 206.47% from $22.62M to -$24.08M.
D
Sell
3/11/2016Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D+ from C on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Total revenue declined 25.58% from $391 to $291.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to D+ from C on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Total revenue declined 25.58% from $391 to $291.
C
Hold
4/25/2014Downgrade
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to C from C+ on 4/25/2014 due to a decline in the total return index.
Northwest Biotherapeutics, Inc. (NWBO) was downgraded to C from C+ on 4/25/2014 due to a decline in the total return index.
C
Hold
4/10/2014Upgraded
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to C+ from C on 4/10/2014 due to a significant increase in the volatility index, total return index and valuation index.
Northwest Biotherapeutics, Inc. (NWBO) was upgraded to C+ from C on 4/10/2014 due to a significant increase in the volatility index, total return index and valuation index.
OTC PK
04/02/2025 3:56PM Eastern
Quotes delayed
